Interventional Radiology Treatment for Postoperative Chylothorax

Hoyong Jun, M.D., Saebeom Hur, M.D.

Department of Radiology, Seoul National University Hospital, Seoul, Korea

ARTICLE INFO
Received: May 20, 2020
Revised: June 22, 2020
Accepted: July 1, 2020

Corresponding author
Saebeom Hur
Tel: 82-2-2072-2584
Fax: 82-2-743-6385
E-mail: saebemo.hur@snu.ac.kr

ORCID: https://orcid.org/0000-0003-0787-5101

Postoperative chylothorax is a rare occurrence after various thoracic surgical procedures, but it poses a substantial risk of morbidity and mortality. Thoracic duct embolization (TDE) is currently deemed the optimal treatment due to its safety and efficacy. This review offers an introduction to interventional options in this setting, detailing the steps of TDE for the edification of those engaged in postoperative care.

Keywords: Intervention, Chylothorax, Thoracic duct, Postoperative care

Introduction

The lymphatic system primarily serves to collect and return interstitial fluid to the venous system [1]. Its bodily components (i.e., retroperitoneal, intestinal, and hepatic) ultimately fuse at the cisterna chyli, traversing the mediastinum via the thoracic duct and eventually draining into the left internal jugular or subclavian vein [2]. The anatomic location of the thoracic duct leaves it vulnerable to injury during various thoracic surgical procedures, such as esophagectomy, lung resection, and mediastinal or aortic surgery, all of which typically are invasive in nature. Fortunately, the incidence of clinically significant chylothorax is relatively low, ranging from 1% to 9% [3-5]. However, chylothorax poses a considerable risk of morbidity and mortality if not appropriately managed at the onset because chylous leakage contains higher nutrient concentrations than non-chylous lymphatic leaks, and the seepage is usually excessive.

Conservative and surgical management of postoperative chylothorax

The optimal clinical management of postoperative chylothorax has yet to be established. At present, therapeutic strategies generally include the following: (1) conservative management, using total parenteral nutrition or medium-chain triglyceride diets; (2) somatostatin and octreotide administration; and (3) surgical intervention involving talc pleurodesis, pleurectomy, or thoracic duct ligation [6]. Surgical ligation of the thoracic duct is an effective means of managing high-output or recurrent chylothorax, with impressive success rates, but the reported rates of procedural morbidity and mortality are as high as 38.8% and 25%, respectively [7-9].

Interventional radiology treatment

In treating chylothorax, the minimal invasiveness and excellent safety profiles of interventional options have fueled their growing popularity [10-13].
Thoracic duct embolization

First introduced in the late 1990s, thoracic duct embolization (TDE) has gradually gained acceptance as first-line therapy for traumatic chylothorax [14]. Some physicians may still be averse to passing a needle through vital abdominal organs, but data on the safety of such procedures continue to mount. There are three major steps to this approach: (1) Lipiodol lymphangiography, (2) thoracic duct access (TDA), and (3) TDE.

Lipiodol lymphangiography

For many years, lymphangiography was synonymous with X-ray imaging of lymphatics opacified by Lipiodol (ethiodized oil, Lipiodol Ultra-Fluid; Guerbet, Villepinte, France). The first use of Lipiodol for this purpose was in the 1960s. Unlike water-soluble iodinated compounds that dissipate rather quickly, Lipiodol remains in the lymphatic system. The transpedal technique was once the mainstay of lymphangiography, entailing direct cannulation of a surgically exposed, minuscule lymphatic channel in the foot. This laborious approach was limited by the sophistication of the requisite operative skills and experience. It was also very time-consuming, slowed by obvious injection constraints and the protracted course of flow from the leg to the trunk.

Intranodal lymphangiography is an effective alternative method of direct lymphatic access that relies on ultrasound guidance. Its launch in 2011 essentially rendered transpedal injections obsolete [15]. In addition to providing very reliable and secure access to the lymphatics, only fundamental skills and standard equipment are called upon for the puncture of centimeter-sized structures. Furthermore, the time invested in lymphatic imaging is dramatically reduced by the ready injectability of contrast agents and the ability to bypass the lower extremity.

In this procedure, the lymph nodes of both inguinal areas are directly pierced under ultrasound guidance by a 26G needle pre-connected to a short accessory tube and a 3-mL polycarbonate syringe. The needle tip is positioned at the transition between the nodal cortex and hilum. Lipiodol is then manually injected at a slow rate, using intermittent fluoroscopy until the lymphatics along the upper lumbar region and the cisterna chyli are opacified (Fig. 1) [16,17].

Thoracic duct access

A 15-cm or 21-cm 21G Chiba needle is advanced to the target structure (cisterna chyli, its major tributary, or an even lower segment of the thoracic duct) under fluoroscopic guidance, and puncture is achieved. A relatively stiff guidewire (0.3556 mm or 0.4572 mm) is then passed through the needle into the cisterna chyli and, eventually, the thoracic duct. Next, a microcatheter is inserted over the guidewire into the thoracic duct. While injecting 5–10 mL of iodinated water-soluble contrast (0.3–1 mL/sec) via a microcatheter, digital subtraction lymphangiography is performed to identify the point(s) of leakage.

Embolization

Once leakage of lymphatic fluid is confirmed by lymphangiography, the entire segment of the thoracic duct is embolized using a combination of microcoils and n-butyl-2-cyanoacrylate (NBCA) liquid glue (Histoacryl; B. Braun Medical Inc., Melsungen, Germany) plus Lipiodol at a ratio of 1:1.5–1:3 (usually 1:2). This is the most commonly applied technique (Fig. 2).

In a meta-analysis, the clinical success rate of TDE in
treating traumatic chylothorax proved to be 92.4%, assuming no technical impediments. The problem is that the pooled technical success rate of TDE, on a per-protocol basis, was only 63.1% [18]. Of the 3 steps involved in the process, TDA is paramount in terms of difficulty and thus dictates the technical outcomes of TDE. However, it is our contention that technical success approaches 90% at experienced centers offering advanced lymphangiography and other forms of interventions.

Despite the high clinical success rate of TDE, some patients do not respond well, and the chylothorax persists. There are several explanations for this, the first being incomplete ductal occlusion due to the inappropriate usage of embolic agents. A dilute mixture of NBCA or a steeper Lipiodol ratio (beyond 1:4) might account for this [19]. Another reason may be the existence of collateral channels that continue to leak chylous fluid. Finally, translocation of chylous ascites is quite conceivable, and can manifest as chylothorax, especially if the diaphragmatic barrier between compartments is damaged during the original surgery. In such circumstances, occlusion of the thoracic duct by embolization or ligation may substantially aggravate symptoms. The decision to perform TDE should, therefore, proceed cautiously if evidence of leakage is not found on Lipiodol lymphangiography or digital subtraction lymph-angiography.

Contraindications and complications of thoracic duct embolization

TDE may be contemplated in any situation amenable to thoracic duct ligation. The goal of each procedure is the same. However, conditions that increase TDA risk may be relative contraindications. Pertinent examples are active abdominal infection, aortic aneurysm, and pancreatitis.

In general, needle penetration of various abdominal organs during TDA is considered safe. However, the gallbladder should be avoided, because there is a potential for bile peritonitis [20]. As with surgical ligation of the thoracic duct, leg swelling (7%) or diarrhea (8%) may develop after TDE during long-term follow-up [11]. Other possible complications include systemic or pulmonary embolization of Lipiodol/glue, bleeding, and allergic reactions to the contrast agent.

Therapeutic Lipiodol lymphangiography

Originally, Lipiodol lymphangiography was intended to visualize leakage points or the cisterna chyli during TDE. Nevertheless, its therapeutic ramifications for refractory lymphatic leakage have since drawn attention [21-26]. Lipiodol-induced selective blockade of pathologic lymph ducts and the sterile inflammatory reactions that occur are believed to produce scarring, encouraging the resolution of lymphatic leakage within several days or weeks [27]. A hypothetical scenario is the saturation of central lymphatics with viscous Lipiodol, with the goal of redirecting flow through existing peripheral lymphovenous connections [2]. Unfortunately, a high proportion of patients fail to respond as anticipated, especially those with higher drainage volumes who are most in need of definitive treatment.

Thoracic duct disruption

Thoracic duct disruption (TDD) is usually performed as a bail-out procedure if TDA is prohibited by technical issues. The aim is to macerate the cisterna chyli or the main retroperitoneal lymphatic channels through multiple needle punctures, thereby reducing downstream lymphatic flow and allowing leaks to heal spontaneously [10,14,28]. Alternatively, the mechanism of action may well be the Lipiodol effect, the inflow of venous blood through disrupted lymphatic vessels, or the pressure exerted upstream on thoracic duct by hematomas formed at puncture sites [28]. In a meta-analysis, the pooled TDD clinical success
rate on a per-protocol basis was 60.8%, which is much less than that of TDE (79.4%) and only slightly better than that of lymphangiography (56.6%) [18]. This suggests that the efficacy of TDD derives fundamentally from lymphangiography, and that it confers no real clinical benefit by itself.

**Conclusion**

Among the various options for radiologic lymphatic intervention, TDA and TDE are optimal measures, preferable to other available methods (i.e., Lipiodol lymphangiography or TDD) when feasible, as they show superior clinical efficacy. They represent less invasive alternatives to open surgical strategies, such as pleurodesis or thoracic duct ligation, in the treatment of high-output chylothorax.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

This research was supported by the Basic Science Research Program of the National Research Foundation of Korea (Grant no., NRF-2018R1C1B6007875), funded by the Ministry of Science, ICT and Future Planning.

**ORCID**

Hoyong Jun: https://orcid.org/0000-0002-2628-3542
Saebeom Hur: https://orcid.org/0000-0003-0787-5101

**References**

1. Ikomi F, Kawai Y, Ohhashi T. Recent advance in lymph dynamic analysis in lymphatics and lymph nodes. Ann Vasc Dis 2012;5:258-68.
2. Hsu MC, Itkin M. Lymphatic anatomy. Tech Vasc Interv Radiol 2016;19:247-54.
3. Dougenis D, Walker WS, Cameron EW, Walbaum PR. Management of chylothorax complicating extensive esophageal resection. Surg Gynecol Obstet 1992;174:501-6.
4. Lai FC, Chen L, Tu YR, Lin M, Li X. Prevention of chylothorax complicating extensive esophageal resection by mass ligation of thoracic duct: a random control study. Ann Thorac Surg 2011;91:1770-4.
5. Mishra PK, Saluja SS, Ramasawamy D, Bains SS, Haque PD. Thoracic duct injury following esophagectomy in carcinoma of the esophagus: ligation by the abdominal approach. World J Surg 2013;37:141-6.
6. Seeliger B, Alesina PF, Walz MK. Posterior retroperitoneoscopic thoracic duct ligation: a novel surgical approach. Surg Endosc 2018;32:3732-7.
7. Paul S, Altorki NK, Port JL, Stiles BM, Lee PC. Surgical management of chylothorax. Thorac Cardiovasc Surg 2009;57:226-8.
8. Schild HH, Strassburg CP, Welz A, Kalf J. Treatment options in patients with chylothorax. Dtsch Arztebl Int 2013;110:819-26.
9. Cerfolio RJ, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Postoperative chylothorax. J Thorac Cardiovasc Surg 1996;112:1361-6.
10. Itkin M, Kucharczuk JC, Kwak A, Trerotola SO, Kaiser LR. Nonoperative thoracic duct embolization for traumatic thoracic duct leak: experience in 109 patients. J Thorac Cardiovasc Surg 2010;139:584-90.
11. Laslett D, Trerotola SO, Itkin M. Delayed complications following technically successful thoracic duct embolization. J Vasc Interv Radiol 2012;23:76-9.
12. Pamarthi V, Stecker MS, Schenker MP, et al. Thoracic duct embolization and disruption for treatment of chyrous effusions: experience with 105 patients. J Vasc Interv Radiol 2014;25:1398-404.
13. Yannes M, Shin D, McCluskey K, Varma R, Santos E. Comparative analysis of intranodal lymphangiography with percutaneous intervention for postsurgical chyrous effusions. J Vasc Interv Radiol 2017;28:704-11.
14. Cope C, Kaiser LR. Management of unremitting chylothorax by percutaneous embolization and blockage of retroperitoneal lymphatic vessels in 42 patients. J Vasc Interv Radiol 2002;13:1139-48.
15. Rajebi MR, Chaudry G, Padua HM, et al. Intranodal lymphangiography: feasibility and preliminary experience in children. J Vasc Interv Radiol 2011;22:1300-5.
16. Kim SW, Hur S, Kim SY, et al. The efficacy of lymph node embolization using N-butyl cyanoacrylate compared to ethanol sclerotherapy in the management of symptomatic lymphorrhoea after pelvic surgery. J Vasc Interv Radiol 2019;30:195-202.
17. Bielas S, Pardina M. Refractory chylothorax: where do we go now? Curr Pulmonol Rep 2019;8:60-7.
18. Kim PH, Tsao J, Shin JH. Lymphatic interventions for chylothorax: a systematic review and meta-analysis. J Vasc Interv Radiol 2018;29:194-202.
19. Kuetting D, Schild HH, Pieper CC. In vitro evaluation of the polymerization properties of N-butyl cyanoacrylate/iodized oil mixtures for lymphatic interventions. J Vasc Interv Radiol 2019;30:110-7.
20. Schild HH, Pieper CC. Where have all the punctures gone?: an analysis of thoracic duct embolizations. J Vasc Interv Radiol 2020;31:74-9.
21. Kortes N, Radeleff B, Sommer CM, et al. Therapeutic lymphangiography and CT-guided sclerotherapy for the treatment of refractory
lymphatic leakage. J Vasc Interv Radiol 2014;25:127-32.
22. Matsumoto T, Yamagami T, Kato T, et al. The effectiveness of lymphangiography as a treatment method for various chyle leakages. Br J Radiol 2009;82:286-90.
23. Kos S, Haueisen H, Lachmund U, Roeren T. Lymphangiography: forgotten tool or rising star in the diagnosis and therapy of postoperative lymphatic vessel leakage. Cardiovasc Intervent Radiol 2007;30:968-73.
24. Gruber-Rouh T, Naguib NNN, Lehnert T, et al. Direct lymphangiography as treatment option of lymphatic leakage: indications, outcomes and role in patient’s management. Eur J Radiol 2014;83:2167-71.
25. Alejandre-Lafont E, Krompiec C, Rau WS, Krombach GA. Effectiveness of therapeutic lymphography on lymphatic leakage. Acta Radiol 2011;52:305-11.
26. Kawasaki R, Sugimoto K, Fujii M, et al. Therapeutic effectiveness of diagnostic lymphangiography for refractory postoperative chylothorax and chylous ascites: correlation with radiologic findings and preceding medical treatment. AJR Am J Roentgenol 2013;201:659-66.
27. Pieper CC, Hur S, Sommer CM, et al. Back to the future: lipiodol in lymphography: from diagnostics to theranostics. Invest Radiol 2019;54:600-15.
28. Binkert CA, Yucel EK, Davison BD, Sugarbaker DJ, Baum RA. Percutaneous treatment of high-output chylothorax with embolization or needle disruption technique. J Vasc Interv Radiol 2005;16:1257-62.